SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Osemeke U. Osokogu, Federica Fregonese, Carmen Ferrajolo, Katia Verhamme, Sandra de Bie, Geert ’t Jong, Mariana Catapano, Daniel Weibel, Florentia Kaguelidou, Wichor M. Bramer, Yingfen Hsia, Ian C. K. Wong, Madlen Gazarian, Jan Bonhoeffer, Miriam Sturkenboom, Pediatric Drug Safety Signal Detection: A New Drug–Event Reference Set for Performance Testing of Data-Mining Methods and Systems, Drug Safety, 2015, 38, 2, 207

    CrossRef

  2. 2
    Janne Kaergaard Mortensen, Grethe Andersen, Safety of selective serotonin reuptake inhibitor treatment in recovering stroke patients, Expert Opinion on Drug Safety, 2015, 14, 6, 911

    CrossRef

  3. 3
    Chi-Un Pae, Sheng-Min Wang, Soo-Jung Lee, Changsu Han, Ashiwn A Patkar, Prakash S Masand, Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram, Expert Opinion on Drug Safety, 2014, 13, 2, 197

    CrossRef

  4. 4
    Sheng-Min Wang, Chi-Un Pae, How much to worry about the FDA warning in the use of citalopram?, Expert Review of Neurotherapeutics, 2013, 13, 8, 883

    CrossRef

  5. 5
    Charles E. Leonard, Warren B. Bilker, Craig Newcomb, Stephen E. Kimmel, Sean Hennessy, Additional data on citalopram and the risk of sudden cardiac death and ventricular arrhythmia, Pharmacoepidemiology and Drug Safety, 2012, 21, 3
  6. 6
    Robert Temple, Thomas Laughren, Norman Stockbridge, Removal from labeling of 60-mg citalopram dose, Pharmacoepidemiology and Drug Safety, 2012, 21, 7